

FORM PTO-1449 (Modified [0-1])

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT(S)' INFORMATION DISCLOSURE
STATEMENT

(Use several sheets if necessary)



ATTY. DOCKET NO.

13761-7011

SERIAL NO.

09/743,684

RECEIVED

FEB 05 2003

INVENTOR
Parkash S. Gill

TECH CENTER 1600/290

FILING DATE
April 23, 2001GROUP ART UNIT
1642

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAM'R INITIAL		DOCUMENT NUMBER	DATE	NAME	Class	Subclass	Filing Date If Appropriate
ALH	*A1	5,696,080	December 9, 1997	O'Brien et al.			
	A2						
	A3						

FOREIGN PATENT DOCUMENTS

EXAM'R INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	Subclass	TRANSLAT'N	
ALH	*B1	95/03821	February 9, 1995	WO			yes	no
	B2							
	B3							
	B4							
	B5							

OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.)

*C1	Collard, Michael W. et al., "Biosynthesis and Molecular Cloning of Sulfated Glycoprotein 1 Secreted by Rat Sertoli Cells: Sequence Similarity with the 70 KiloDalton Precursor to Sulfatide/G _{M1} Activator," (1988) <i>Biochemistry</i> , 27:4557-4564.
*C2	Genbank Accession No.: AAA 60303 Prosaposin
*C23	Hiraiwa, Masao et al., "The Effect of Carbohydrate Removal on Stability and Activity of Saposin B ¹ ," (1993) <i>Arch. Biochem. Biophys.</i> 303:326.
*C4	Kase, Ryoichi et al. "Only sphingolipid activator protein B(SAP-B or saposin B) stimulates the degradation of globo triaosylceramide by recombinant human lysosomal α -galactosidase in a detergent-free liposomal system," (1996) <i>FEBS Lett.</i> 393:74-76.
*C5	Kretz, Keith A. et al., "Characterization of a mutation in a family with saposin B deficiency: A glycosylation site defect," (1990) <i>Proc. Nat'l Acad. Sci. USA</i> , 87:2541-2544.
*C6	Lamontagne, Sonia et al., "Modulation of Human Saposin B Sphingolipid-binding Specificity by Alternative Splicing," (1994) <i>Biol. Chem.</i> , 269:20528-20532.
*C7	Sano, Akira et al., "Sphingolipid Hydrolase Activator Proteins and Their Precursors," (1989) <i>Biochem. Biophys. Res. Commun.</i> , 165:1191-1197.
*C8	Zetter, Bruce R., "Angiogenesis And Tumor Metastasis," (1998) <i>Annu. Rev. Med.</i> 49: 407-24.

Anne L. Sullivan

5/17/04

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).